KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Gains from Sales and Divestitures (2016 - 2025)

Historic Gains from Sales and Divestitures for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Q3 2025 value amounting to $590587.0.

  • CRISPR Therapeutics AG's Gains from Sales and Divestitures rose 5204.62% to $590587.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $590587.0, marking a year-over-year increase of 5204.62%. This contributed to the annual value of $450701.0 for FY2024, which is 6223.47% up from last year.
  • CRISPR Therapeutics AG's Gains from Sales and Divestitures amounted to $590587.0 in Q3 2025, which was up 5204.62% from $501884.0 recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Gains from Sales and Divestitures registered a high of $590587.0 during Q3 2025, and its lowest value of $109355.0 during Q1 2021.
  • Moreover, its 5-year median value for Gains from Sales and Divestitures was $270626.0 (2023), whereas its average is $287310.9.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Gains from Sales and Divestitures skyrocketed by 208710.0% in 2021, and later plummeted by 4775.78% in 2022.
  • CRISPR Therapeutics AG's Gains from Sales and Divestitures (Quarter) stood at $455440.0 in 2021, then plummeted by 47.76% to $237932.0 in 2022, then increased by 16.76% to $277808.0 in 2023, then soared by 62.23% to $450701.0 in 2024, then skyrocketed by 31.04% to $590587.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $590587.0 for Q3 2025, versus $501884.0 for Q2 2025 and $396943.0 for Q1 2025.